Imunon (IMNN) Stock News

IMUNON (NASDAQ: IMNN) has secured a private placement offering priced at-the-market, raising $3.25 million initially through the sale of 7,222,223 shares of common stock (or pre-funded warrants) at $0.45 per share. The deal includes short-term warrants to purchase up to 14,444,446 additional shares, which could generate up to $6.5 million in additional proceeds if fully exercised.

The warrants will be exercisable at $0.45 per share upon stockholder approval and will expire after three years. The offering, expected to close around May 27, 2025, is being managed by H.C. Wainwright & Co. as exclusive placement agent, with Brookline Capital Markets as financial advisor. The company plans to use the proceeds for working capital and general corporate purposes.

IMUNON (NASDAQ: IMNN) has announced groundbreaking results from its Phase 2 OVATION 2 Study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The study demonstrated a 13-month increase in median overall survival (46 vs. 33 months) and a 3-month improvement in progression-free survival (14.9 vs. 11.9 months) compared to standard care.

Notably, patients receiving PARP inhibitors alongside IMNN-001 showed exceptional results, with median overall survival not yet reached after 5+ years versus 37 months in the control group. The therapy was well-tolerated with no serious immune-related adverse events. Based on these promising results, IMUNON has initiated its pivotal Phase 3 OVATION 3 Study at two sites.

The findings will be presented at the 2025 ASCO Annual Meeting and published in Gynecologic Oncology.

IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, has announced the withdrawal of its Form S-1 Registration Statement (No. 333-286403) with the SEC. The registration statement, originally filed on April 4, 2025, was withdrawn as the company has decided not to proceed with the planned public offering at this time. The statement had not been declared effective by the SEC, and no securities were sold in connection with the offering.

IMUNON announced promising 6-month data from its Phase 1 trial of IMNN-101, a DNA plasmid vaccine using their PlaCCine® platform for COVID-19 protection. The trial, involving 24 healthy volunteers, showed durability of protection with up to 3-fold median increase in neutralizing antibodies at 6 months post-single dose. The highest dose cohorts (2.0mg and 1.0mg) demonstrated stronger immune responses compared to the 0.5mg cohort, with some participants showing up to 8-fold increases. The vaccine targets the SARS-CoV-2 Omicron XBB1.5 variant and showed cross-reactivity against newer variants. IMNN-101 demonstrated key advantages over mRNA vaccines, including better temperature stability and easier manufacturing. The vaccine maintained its safety profile with no serious adverse effects reported.

IMUNON (NASDAQ: IMNN) reported Q1 2025 financial results and significant progress in its clinical programs. The company initiated its first site for the Phase 3 OVATION 3 study of IMNN-001 in advanced ovarian cancer treatment. New data from the Phase 2 OVATION 2 study was accepted for oral presentation at the 2025 ASCO Annual Meeting. The company reported a net loss of $4.1 million ($0.28 per share) compared to $4.9 million ($0.52 per share) in Q1 2024. Operating expenses decreased 18% to $4.1 million. Cash and equivalents stood at $2.9 million, sufficient to fund operations into late Q2 2025. Recent translational data showed a 20% increase in IL-12 levels in patients treated with IMNN-001 plus standard chemotherapy. The company also reported positive immunogenicity data from its Phase 1 trial of PlaCCine DNA vaccine for COVID-19.

IMUNON (NASDAQ: IMNN) has initiated its first trial site at Washington University School of Medicine for the pivotal Phase 3 OVATION 3 study of IMNN-001, a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer. The study will compare IMNN-001 plus neoadjuvant and adjuvant chemotherapy against standard care alone. The trial will randomize patients 1:1, focusing on women with stage 3C or 4 ovarian cancer. IMNN-001 is notable as the first immunotherapy showing meaningful overall survival benefit in Phase 2 trials for advanced ovarian cancer patients. The primary endpoint is overall survival, with secondary endpoints including surgical response score and time to second-line treatment. New data from the Phase 2 OVATION 2 Study will be presented at the upcoming 2025 ASCO Annual Meeting.

IMUNON (NASDAQ: IMNN) announced that data from their Phase 1/2 OVATION 2 trial for IMNN-001, a DNA-mediated immunotherapy for advanced epithelial ovarian cancer, will be published in Gynecologic Oncology on June 3, 2025. The study evaluates IMNN-001's intraperitoneal administration combined with neoadjuvant and adjuvant chemotherapy. The data will also be presented at the 2025 ASCO Annual Meeting in Chicago through an oral presentation led by Dr. Premal H. Thaker from Washington University School of Medicine. CEO Stacy Lindborg emphasized that the dual presentation platforms highlight both the urgent need for new ovarian cancer treatments and the potential of IMUNON's TheraPlas® platform technology.

IMUNON (NASDAQ: IMNN) has scheduled a conference call for Monday, May 12, 2025, at 11:00 a.m. ET to discuss its first quarter 2025 financial results and provide updates on its clinical development programs. The company will specifically focus on the progress of IMNN-001, their DNA-based interleukin-12 immunotherapy, including developments toward initiating a Phase 3 clinical trial in advanced ovarian cancer.

Participants can join via phone at 833-816-1132 (North America) or 412-317-0711 (International). The call recording will be available until May 26, 2025, with replay access code 2322959. A webcast will also be accessible and archived online for 90 days.

IMUNON (NASDAQ: IMNN) announced that new survival data from its Phase 2 OVATION 2 Study of IMNN-001 for treating newly diagnosed advanced ovarian cancer will be presented at the 2025 ASCO Annual Meeting (May 30-June 3, Chicago).

The company recently aligned with the FDA on the protocol for the Phase 3 OVATION 3 clinical trial and has begun trial site activation. IMNN-001, based on their TheraPlas® technology platform, is an IL-12 DNA plasmid vector in a nanoparticle delivery system that enables local production of IL-12 protein in the tumor environment.

IMNN-001 is notable as the first and only IL-12 immunotherapy showing clinical effectiveness, including survival benefits, in frontline treatment for advanced (Stage III/IV) ovarian cancer patients. The presentation at ASCO will be delivered by Dr. Premal H. Thaker from Washington University School of Medicine.